To extend the findings of a previous clinical trial suggesting combined abacavir (ABC), lamivudine (3TC), and zidovudine (AZT) reduces type I interferon (IFN) signalling in Aicardi–Goutières syndrome (AGS). This evidence concerns the gene IFNA1 and Aicardi-Goutieres syndrome.